82 FR 25295 - National Institute of General Medical Sciences; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 104 (June 1, 2017)

Page Range		25295-25296
FR Document		2017-11352

Federal Register, Volume 82 Issue 104 (Thursday, June 1, 2017)

[Federal Register Volume 82, Number 104 (Thursday, June 1, 2017)]
[Notices]
[Pages 25295-25296]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-11352]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of General Medical Sciences; Notice of Closed 
Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.


[[Page 25296]]


    Name of Committee: National Institute of General Medical 
Sciences Special Emphasis Panel; Review of COBRE Applications.
    Date: July 19, 2017.
    Time: 8:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Bethesda North Marriott Hotel & Conference Center, 
Montgomery County Conference Center Facility, 5701 Marinelli Road, 
North Bethesda, MD 20852.
    Contact Person: Robert Horowits, Ph.D., Scientific Review 
Officer, National Institute of General Medical Sciences, National 
Institutes of Health, 45 Center Drive, Room 3An.18, Bethesda, MD 
20892-6200, 301-594-6904, [email protected].

    Name of Committee: National Institute of General Medical 
Sciences Special Emphasis Panel; Special Emphasis Panel.
    Date: July 20, 2017.
    Time: 8:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Residence Inn Bethesda Downtown, 7335 Wisconsin Avenue, 
Bethesda, MD 20814.
    Contact Person: Tracy Koretsky, Ph.D., Scientific Review 
Officer, National Institute of General Medical Sciences, National 
Institutes of Health, 45 Center Drive, MSC 6200, Room 3An.12F, 
Bethesda, MD 20892, 301-594-2886, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, 
Minority Biomedical Research Support; 93.821, Cell Biology and 
Biophysics Research; 93.859, Pharmacology, Physiology, and 
Biological Chemistry Research; 93.862, Genetics and Developmental 
Biology Research; 93.88, Minority Access to Research Careers; 93.96, 
Special Minority Initiatives; 93.859, Biomedical Research and 
Research Training, National Institutes of Health, HHS)

    Dated: May 26, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-11352 Filed 5-31-17; 8:45 am]
BILLING CODE 4140-01-P

Federal Register / Vol. 82, No. 104 / Thursday, June 1, 2017 / Notices 25295

Contact Person: Shalanda A. Bynum, MPH, Dehydrogenase 1 (mIDH1) inhibitors for Thus, the compounds of the subject
Ph.D., Scientific Review Officer, Center for the Treatment of Human Cancers. inventions can be used individually or
Scientific Review, National Institutes of Category: Routine. in combination to develop new
Health, 6701 Rockledge Drive, Room 3206, Action Needed By: There is no therapies to treat diseases which result
Bethesda, MD 20892, 301–755–4355, specific date that this needs to be
bynumsa@csr.nih.gov.
from mutant IDH1 activity. The diseases
approved by, but the sooner the caused by mutant IDH1 activity include
This notice is being published less than 15 document is approved, the sooner NIH
days prior to the meeting due to the timing
cancer (e.g., acute myeloid leukemia,
limitations imposed by the review and
can make a potential therapeutic glioma, cholangiocarcinoma and
funding cycle. available to the public. potentially other solid tumors) and
Summary: Administration of an selected rare diseases, such as Ollier
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine; inhibitor of mIDH1 can potentially treat Disease.
93.333, Clinical Research, 93.306, 93.333, cancers resulting from or characterized This notice is made in accordance
93.337, 93.393–93.396, 93.837–93.844, by the presence of mIDH1. Industrial with 35 U.S.C. 209 and 37 CFR part 404.
93.846–93.878, 93.892, 93.893, National partners are being sought for licensing The prospective exclusive license will
Institutes of Health, HHS) and to help further develop this be royalty bearing, and the prospective
Dated: May 26, 2017. technology for use in humans. There are exclusive license may be granted unless
Anna Snouffer, currently few effective therapeutics to within thirty (30) days from the date of
treat resulting from aberrant activity of this published notice, the National
Deputy Director, Office of Federal Advisory
Committee Policy. mIDH1, such as acute myeloid Center for Advancing Translational
leukemia. Sciences receives written evidence and
[FR Doc. 2017–11349 Filed 5–31–17; 8:45 am]
Justification: Although there is no argument that establishes that the grant
BILLING CODE 4140–01–P
specific date requirement, rapid of the license would not be consistent
approval is requested in order to make with the requirements of 35 U.S.C. 209
DEPARTMENT OF HEALTH AND a potential therapeutic available to the and 37 CFR part 404.
HUMAN SERVICES public quickly. Complete applications for a license in
SUPPLEMENTARY INFORMATION: the prospective field of use that are filed
National Institutes of Health in response to this notice will be treated
Intellectual Property as objections to the grant of the
Prospective Grant of Exclusive Patent 1. International Application No. PCT/US15/ contemplated Exclusive Patent License
License: Mutant IDH1 Inhibitors Useful 067406 filed on 12/22/2015 which is Agreement. Comments and objections
for Treating Cancer entitled ‘‘Mutant IDH1 Inhibitors Useful submitted to this notice will not be
for Treating Cancer’’ (HHS Ref. No: E– made available for public inspection
AGENCY: National Institutes of Health, 243–2014/0–PCT–02), and and, to the extent permitted by law, will
HHS. 2. U.S. Provisional Application No. 62/
353298 filed on 06/22/2016 which is
not be released under the Freedom of
ACTION: Notice. entitled ‘‘Mutant IDH1 Inhibitors Useful Information Act, 5 U.S.C. 552.
for Treating Cancer’’ (HHS Ref. No. E– Dated: May 25, 2017.
SUMMARY: National Center for 189–2016/0–US–01)
Advancing Translational Sciences, an Pamela McInnes,
institute of the National Institutes of The patent rights in these inventions Deputy Director, Office of the Director,
Health, Department of Health and have been assigned and/or exclusively National Center for Advancing Translational
licensed to the government of the Sciences.
Human Services, is contemplating the
grant of an exclusive patent license to United States of America and the [FR Doc. 2017–11241 Filed 5–31–17; 8:45 am]
practice the inventions embodied in the University of North Carolina at Chapel BILLING CODE 4140–01–P

Patent Applications listed in the Hill.
Summary Information section of this The prospective exclusive license
notice to GeneXion Oncology, Inc., territory may be worldwide and the field DEPARTMENT OF HEALTH AND
located in New York, NY. of use may be limited to the use of HUMAN SERVICES
Licensed Patent Rights for the following:
DATES: Only written comments and/or National Institutes of Health
‘‘Therapeutics for cancers in humans
applications for a license which are which result from or characterized by
received by the National Center for National Institute of General Medical
the presence of mutant IDH1.’’
Advancing Translational Sciences on or The inventions relate to a series of Sciences; Notice of Closed Meetings
before July 3, 2017 will be considered. novel compounds that potently and Pursuant to section 10(d) of the
ADDRESSES: Requests for copies of the selectively inhibit mIDH1. These Federal Advisory Committee Act, as
patent application, inquiries, and compounds reduce 2–HG levels in cell amended (5 U.S.C. App.), notice is
comments relating to the contemplated lines in vitro as well as in human cancer hereby given of the following meetings.
exclusive license should be directed to: cells grown in mouse xenografts in vivo. The meetings will be closed to the
Sury Vepa, Ph.D., J.D., Senior Licensing These compounds show greater than public in accordance with the
and Patenting Manager, National Center 250-fold selectivity for the mutant provisions set forth in sections
for Advancing Translational Sciences, enzyme over the wild-type, show 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
NIH, 9800 Medical Center Drive, favorable in vitro stability (in mouse, as amended. The grant applications and
Rockville, MD 20850, Phone: 301–217– rat, dog and human hepatocyte exposure the discussions could disclose
mstockstill on DSK30JT082PROD with NOTICES

9197, Fax: 301–217–5736, or email studies), are AMES negative, and exhibit confidential trade secrets or commercial
sury.vepa@nih.gov. A signed no significant metabolic CYP liabilities. property such as patentable material,
Confidential Disclosure Agreement may These compounds possess very and personal information concerning
be required to receive copies of the favorable in vivo rodent individuals associated with the grant
patent applications. pharmacokinetics and bioavailability applications, the disclosure of which
Licensing Availability: The and are well tolerated in rodents, even would constitute a clearly unwarranted
Development of mutant Isocitrate when dosed at high levels. invasion of personal privacy.

VerDate Sep<11>2014 18:32 May 31, 2017 Jkt 241001 PO 00000 Frm 00072 Fmt 4703 Sfmt 4703 E:\FR\FM\01JNN1.SGM 01JNN1

25296 Federal Register / Vol. 82, No. 104 / Thursday, June 1, 2017 / Notices

Name of Committee: National Institute of individuals associated with the grant Agenda: To review and evaluate grant
General Medical Sciences Special Emphasis applications, the disclosure of which applications.
Panel; Review of COBRE Applications. would constitute a clearly unwarranted Place: Ritz-Carlton Hotel, 1700 Tysons
Date: July 19, 2017. Boulevard, McLean, VA 22102.
invasion of personal privacy.
Time: 8:00 a.m. to 5:00 p.m. Contact Person: Brian H. Scott, Ph.D.,
Agenda: To review and evaluate grant Name of Committee: Cardiovascular and Scientific Review Officer, National Institutes
applications. Respiratory Sciences Integrated Review of Health, Center for Scientific Review, 6701
Place: Bethesda North Marriott Hotel & Group; Myocardial Ischemia and Metabolism Rockledge Drive, Bethesda, MD 20892, 301–
Conference Center, Montgomery County Study Section. 827–7490, brianscott@mail.nih.gov.
Conference Center Facility, 5701 Marinelli Date: June 22–23, 2017. Name of Committee: Integrative,
Road, North Bethesda, MD 20852. Time: 8:00 a.m. to 6:00 p.m. Functional and Cognitive Neuroscience
Contact Person: Robert Horowits, Ph.D., Agenda: To review and evaluate grant Integrated Review Group; Somatosensory and
Scientific Review Officer, National Institute applications. Chemosensory Systems Study Section.
of General Medical Sciences, National Place: Hotel Kabuki, 1625 Post Street, San Date: June 26–27, 2017.
Institutes of Health, 45 Center Drive, Room Francisco, CA 94115. Time: 8:00 a.m. to 5:00 p.m.
3An.18, Bethesda, MD 20892–6200, 301– Contact Person: Kimm Hamann, Ph.D., Agenda: To review and evaluate grant
594–6904, horowitr@mail.nih.gov. Scientific Review Officer, Center for applications.
Name of Committee: National Institute of Scientific Review, National Institutes of Place: Washington Plaza Hotel, 10 Thomas
General Medical Sciences Special Emphasis Health, 6701 Rockledge Drive, Room 4118A, Circle NW., Washington, DC 20005.
Panel; Special Emphasis Panel. MSC 7814, Bethesda, MD 20892, 301–435– Contact Person: M. Catherine Bennett,
Date: July 20, 2017. 5575, hamannkj@csr.nih.gov. Ph.D., Scientific Review Officer, Center for
Time: 8:00 a.m. to 5:00 p.m. Name of Committee: Center for Scientific Scientific Review, National Institutes of
Agenda: To review and evaluate grant Review Special Emphasis Panel; Member Health, 6701 Rockledge Drive, Room 5182,
applications. Conflict: Cognition and Perception. MSC 7846, Bethesda, MD 20892, 301–435–
Place: Residence Inn Bethesda Downtown, Date: June 22, 2017. 1766, bennettc3@csr.nih.gov.
7335 Wisconsin Avenue, Bethesda, MD Time: 10:00 a.m. to 1:00 p.m. Name of Committee: Center for Scientific
20814. Agenda: To review and evaluate grant Review Special Emphasis Panel;
Contact Person: Tracy Koretsky, Ph.D., applications. Fellowships: Biophysical, Physiological,
Scientific Review Officer, National Institute Place: National Institutes of Health, 6701 Pharmacological and Bioengineering
of General Medical Sciences, National Rockledge Drive, Bethesda, MD 20892 Neuroscience.
Institutes of Health, 45 Center Drive, MSC (Telephone Conference Call). Date: June 26–27, 2017.
6200, Room 3An.12F, Bethesda, MD 20892, Contact Person: Biao Tian, Ph.D., Scientific Time: 8:00 a.m. to 5:00 p.m.
301–594–2886, tracy.koretsky@nih.gov. Review Officer, Center for Scientific Review, Agenda: To review and evaluate grant
(Catalogue of Federal Domestic Assistance National Institutes of Health, 6701 Rockledge applications.
Program Nos. 93.375, Minority Biomedical Drive, Room 3089B, MSC 7848, Bethesda, Place: The St. Regis Washington DC, 923
Research Support; 93.821, Cell Biology and MD 20892, 301–402–4411, tianbi@ 16th Street NW., Washington, DC 20006.
Biophysics Research; 93.859, Pharmacology, csr.nih.gov. Contact Person: Paula Elyse Schauwecker,
Physiology, and Biological Chemistry Name of Committee: Center for Scientific Ph.D., Scientific Review Officer, National
Research; 93.862, Genetics and Review Special Emphasis Panel; Small Institutes of Health, Center for Scientific
Developmental Biology Research; 93.88, Business: Endocrinology, Metabolism, Review, 6701 Rockledge Drive, Room 5211,
Minority Access to Research Careers; 93.96, Nutrition and Reproductive Sciences. Bethesda, MD 20892, 301–760–8207,
Special Minority Initiatives; 93.859, Date: June 26–27, 2017. schauweckerpe@csr.nih.gov.
Biomedical Research and Research Training, Time: 8:00 a.m. to 5:00 p.m. Name of Committee: Center for Scientific
National Institutes of Health, HHS) Agenda: To review and evaluate grant Review Special Emphasis Panel; Health
Dated: May 26, 2017. applications. Informatics.
Place: Bethesda Marriott Suites, 6711 Date: June 26–27, 2017.
Melanie J. Pantoja,
Democracy Boulevard, Bethesda, MD 20817. Time: 8:00 a.m. to 5:00 p.m.
Program Analyst, Office of Federal Advisory Contact Person: Clara M Cheng, Ph.D., Agenda: To review and evaluate grant
Committee Policy. Scientific Review Officer, Center for applications.
[FR Doc. 2017–11352 Filed 5–31–17; 8:45 am] Scientific Review, National Institutes of Place: Embassy Suites at the Chevy Chase
BILLING CODE 4140–01–P Health, 6701 Rockledge Drive, Room 6170, Pavilion, 4300 Military Road NW.,
MSC 7892, Bethesda, MD 20892, 301–435– Washington, DC 20015.
1041, chengc@csr.nih.gov. Contact Person: Michael L. Bloom, Ph.D.,
DEPARTMENT OF HEALTH AND Name of Committee: Biobehavioral and Scientific Review Officer, Center for
HUMAN SERVICES Behavioral Processes Integrated Review Scientific Review, National Institutes of
Group; Cognition and Perception Study Health, 6701 Rockledge Drive, Room 6187,
National Institutes of Health Section. MSC 7804, Bethesda, MD 20892, 301–451–
Date: June 26–27, 2017. 0132, bloomm2@mail.nih.gov.
Center for Scientific Review; Notice of Time: 8:00 a.m. to 2:00 p.m. Name of Committee: Center for Scientific
Closed Meetings Agenda: To review and evaluate grant Review Special Emphasis Panel; Innovative
applications. Immunology.
Pursuant to section 10(d) of the Place: Ritz-Carlton Hotel, 1700 Tysons Date: June 26, 2017.
Federal Advisory Committee Act, as Boulevard, McLean, VA 22102. Time: 8:00 a.m. to 5:00 p.m.
amended (5 U.S.C. App.), notice is Contact Person: Andrea B. Kelly, Ph.D., Agenda: To review and evaluate grant
hereby given of the following meetings. Scientific Review Officer, Center for applications.
The meetings will be closed to the Scientific Review, National Institutes of Place: Courtyard by Marriott, 5520
Health, 6701 Rockledge Drive, Room 3184, Wisconsin Avenue, Chevy Chase, MD 20815.
public in accordance with the
mstockstill on DSK30JT082PROD with NOTICES

MSC 7770, Bethesda, MD 20892, 301–455– Contact Person: Andrea Keane-Myers,
provisions set forth in sections 1761, kellya2@csr.nih.gov. Ph.D., Scientific Review Officer, Center for
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Scientific Review, National Institutes of
Name of Committee: Center for Scientific
as amended. The grant applications and Review Special Emphasis Panel; RFA Panel: Health, 6701 Rockledge Drive, Room 4218,
the discussions could disclose Molecular and Cellular Substrates of Bethesda, MD 20892, 301–435–1221,
confidential trade secrets or commercial Complex Brain Disorders. andrea.keane-myers@nih.gov.
property such as patentable material, Date: June 26, 2017. Name of Committee: Center for Scientific
and personal information concerning Time: 8:00 a.m. to 6:00 p.m. Review Special Emphasis Panel;

VerDate Sep<11>2014 18:32 May 31, 2017 Jkt 241001 PO 00000 Frm 00073 Fmt 4703 Sfmt 4703 E:\FR\FM\01JNN1.SGM 01JNN1

Document Created: 2017-06-01 03:05:08
Document Modified: 2017-06-01 03:05:08

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		July 19, 2017.
FR Citation		82 FR 25295

82 FR 25295 - National Institute of General Medical Sciences; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 82, Issue 104 (June 1, 2017)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health